CSIMarket Company Name, Ticker, Customers, else..


Eli Lilly And Company  (NYSE: LLY)
Other Ticker:  
 

Eli Lilly And Company

LLY's Fundamental analysis



Looking into Eli Lilly growth rates, revenue grew by 44.68 % in IV. Quarter 2024 from the same quarter a year ago. Ranking at No. 291

Major Pharmaceutical Preparations industry recorded growth of revenues by 11.85 %

Eli Lilly's net income grew by 101.39 % in IV. Quarter 2024 year on year, above company average,

• More on LLY's Growth


Eli Lilly
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Eli Lilly PEG ratio is at 0.75 Company is currently trading with Price to Cash flow multiple of 1778.43 in trailing twelve-month period.
Company
75.7
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 17.76.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.


• More on LLY's Valuation
 
 Total Debt (Millions $) 33,644
 Dividend TTM ($) 5.18 $
 Dividend Yield TTM (%) 0.58 %
 Revenue/Employee (TTM) $ 1,047,505
 Net Income/Employee (TTM) $ 246,279
 Receivable Turnover (TTM) 4.48
 Tangible Book Value (Per Share $) 2.58

Eli Lilly
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Eli Lilly PEG ratio is at 0.75 Company is currently trading with Price to Cash flow multiple of 1778.43 in trailing twelve-month period.
Company
75.7
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 17.76.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.

Eli Lilly Price to Book Ratio is at 56.05 lower than Industry Avg. of 79.76. and higher than S&P 500 Avg. of 0.01

• More on LLY's Valuation

•  Market Capitalization (Millions $) 799,938
•  Shares Outstanding (Millions) 904
•  Employees 43,000
•  Revenues (TTM) (Millions $) 45,043
•  Net Income (TTM) (Millions $) 10,590
•  Cash Flow (TTM) (Millions $) 450
•  Capital Exp. (TTM) (Millions $) -5,058
•  Total Debt (Millions $) 33,644
•  Dividend TTM ($) 5.18 $
•  Dividend Yield TTM (%) 0.58 %
•  Revenue/Employee (TTM) $ 1,047,505
•  Net Income/Employee(TTM) $ 246,279
•  Receivable Turnover Ratio (TTM) 4.48
•  Tangible Book Value (Per Share $) 2.58

•  Market Capitalization (Millions $) 799,938
•  Shares Outstanding (Millions) 904
•  Employees 43,000
•  Revenues (TTM) (Millions $) 45,043
•  Net Income (TTM) (Millions $) 10,590
•  Cash Flow (TTM) (Millions $) 450
•  Capital Exp. (TTM) (Millions $) -5,058


    LLY's Profitability Comparisons
Eli Lilly achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in IV. Quarter 2024 to 39.44 % from 38.05 % in III. Quarter.

Eli Lilly net profit margin of 32.59 % is currently ranking no. 21 in Major Pharmaceutical Preparations industry, ranking no. 44 in Healthcare sector and number 380 in S&P 500.


Profitability by Segment
Total 8.48 %



  Ratio
•   Capital Ratio (MRQ) 1.15
•  Total Debt to Equity (MRQ) 2.36
•  Tangible Leverage Ratio (MRQ) 26.7
•  Asset Turnover Ratio (TTM) 0.62
•  Inventory Turnover Ratio (TTM) 1.22



Eli Lilly achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in IV. Quarter 2024 to 39.44 % from 38.05 % in III. Quarter.

Eli Lilly net profit margin of 32.59 % is currently ranking no. 21 in Major Pharmaceutical Preparations industry, ranking no. 44 in Healthcare sector and number 380 in S&P 500.

• More on LLY's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com